Related Experiment Video
Updated: May 2, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Pelvic Location Predicts Worse Outcomes in Alveolar Rhabdomyosarcoma: Underuse of Radiotherapy and Missed Survival
Kole Joachim1, Ezekiel Dingle1, Adrian Lin1
1David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
Introduction:
Alveolar rhabdomyosarcoma (ARMS) is a rare, aggressive soft-tissue malignancy occurring mostly in children. Pelvic presentation poses diagnostic and therapeutic challenges due to proximity to critical structures. This study aims to assess the prognostic treatment factors associated with pelvic ARMS.
Methods:
We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database (2000-2021) that included patients with ARMS. Variables included demographics, socioeconomic factors, and treatment modalities. Logistic regression evaluated associations between tumor location and treatment receipt. Cancer-specific mortality was analyzed using Cox proportional hazards regression, with Weibull parametric survival analysis performed to quantify survival time benefits.
Results:
The study included 678 ARMS patients (585 non-pelvic vs. 93 pelvic). Patients with pelvic tumors had significantly higher mortality risk (hazard ratio [HR] = 1.44, 95%-confidence interval [95% CI]: 1.08-1.94, p = 0.014) and were less likely to undergo resection (45.1% vs. 30.1%, p = 0.007). Weibull parametric analysis demonstrated radiation therapy was associated with improved survival in pelvic tumors, with patients receiving radiation having a predicted median survival of 34.7 months compared to 17.0 months for those not receiving radiation (17.7 month difference, p = 0.039). Both radiation therapy (HR = 0.56, 95% CI: 0.43-0.71, p < 0.001) and surgery (HR = 0.61, 95% CI: 0.48-0.78, p < 0.001) were independently associated with decreased cancer-specific mortality.
Conclusions:
Radiation therapy demonstrated a significant survival benefit in pelvic ARMS, emphasizing the need for standardized treatment strategies in high-risk sites.
